Clinical trial
Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced…
NCT00487669 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00487669 |
|---|---|
| Title | Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC) |
| Official title | Phase II Study of the Combination of Paclitaxel Poliglumex (CT-2103, Xyotax) and Pemetrexed (Alimta) for the Treatment of Patients With Advanced Non-small Cell Lung Cancer. |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | CTI BioPharma Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | paclitaxel poliglumex, pemetrexed |
| Enrollment | 14 |
| Start date | Oct 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Jun 18, 2007 |
| Last update posted | Jan 9, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: